We are live on ! Find out more
OMED

OncoMed Pharmaceuticals, Inc.
OMED

Delisted

OMED was delisted on the 22nd of April, 2019.

83 hedge funds and large institutions have $107M invested in OncoMed Pharmaceuticals, Inc. in 2016 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 34 increasing their positions, 20 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

115% more call options, than puts

Call options by funds: $2.25M | Put options by funds: $1.05M

70% more repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 20

10% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 10

0% more funds holding

Funds holding: 8383 (0)

57% less capital invested

Capital invested by funds: $247M → $107M (-$140M)

67% less funds holding in top 10

Funds holding in top 10: 31 (-2)

Holders
83
Holders Change
Holders Change %
0%
% of All Funds
2.21%
Holding in Top 10
1
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-66.67%
% of All Funds
0.03%
New
11
Increased
34
Reduced
20
Closed
10
Calls
$2.25M
Puts
$1.05M
Net Calls
+$1.21M
Net Calls Change
+$174K
Name Holding Trade Value Shares
Change
Change in
Stake
ASP
1
Adams Street Partners
Illinois
$18.6M
BI
2
BVF Inc
California
$13.5M +$4.08M +347,903 +35%
Fidelity Investments
3
Fidelity Investments
Massachusetts
$9.21M -$1.94M -165,117 -15%
BFA
4
BlackRock Fund Advisors
California
$8.32M +$228K +19,418 +2%
Vanguard Group
5
Vanguard Group
Pennsylvania
$6.08M +$1.94M +165,172 +38%
IHM
6
Iguana Healthcare Management
New York
$4.72M +$787K +67,025 +17%
Alyeska Investment Group
7
Alyeska Investment Group
Illinois
$3.29M +$1.95M +165,802 +104%
DGI
8
Disciplined Growth Investors
Minnesota
$3.12M +$4.11K +350 +0.1%
Franklin Resources
9
Franklin Resources
California
$2.97M
BIT
10
BlackRock Institutional Trust
California
$2.68M +$50.9K +4,335 +2%
State Street
11
State Street
Massachusetts
$2.4M +$170K +14,518 +7%
Primecap Management
12
Primecap Management
California
$2.18M +$282K +24,000 +13%
CC
13
Cannell & Co
New York
$2.13M
Northern Trust
14
Northern Trust
Illinois
$2.05M +$35.6K +3,033 +2%
EAM
15
Eventide Asset Management
Massachusetts
$1.92M
First Eagle Investment Management
16
First Eagle Investment Management
New York
$1.86M +$2.17M +184,430 New
Norges Bank
17
Norges Bank
Norway
$1.84M
Bank of America
18
Bank of America
North Carolina
$1.35M -$76.2K -6,492 -5%
Barclays
19
Barclays
United Kingdom
$1.18M +$1.24M +105,972 +916%
BIM
20
Bogle Investment Management
Massachusetts
$1.13M +$1.31M +111,937 New
CS
21
Candriam SCA
Luxembourg
$1.06M -$243K -20,700 -16%
Jennison Associates
22
Jennison Associates
New York
$905K
Bank of New York Mellon
23
Bank of New York Mellon
New York
$865K +$247K +21,037 +33%
CS
24
Credit Suisse
Switzerland
$838K +$36.9K +3,140 +4%
ARTA
25
A.R.T. Advisors
New York
$832K +$966K +82,313 New

OMED Hedge Fund Activity: Q1 2016 in Review

83 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in OncoMed Pharmaceuticals, Inc. (OMED) for Q1 2016, worth a combined $107M — down 57% from $247M a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new OMED positions and 10 closed out — a net gain of 1 holder — while 34 added to existing stakes and 20 trimmed.

The largest buyer was BVF Inc, adding an estimated $4.08M. The largest seller was Visium Asset Management, exiting entirely with an estimated $5.37M sold.

  • 83 institutional investors held OncoMed Pharmaceuticals, Inc. (OMED) as of Q1 2016, unchanged from Q4 2015.
  • Funds reported $107M of OncoMed Pharmaceuticals, Inc. stock for Q1 2016, down 57% quarter-over-quarter.
  • 11 funds opened new OncoMed Pharmaceuticals, Inc. positions in Q1 2016 and 10 closed out, a net change of +1 holder.
  • The largest OncoMed Pharmaceuticals, Inc. buyer in Q1 2016 was BVF Inc, an estimated $4.08M added.
  • The largest OncoMed Pharmaceuticals, Inc. seller in Q1 2016 was Visium Asset Management, an estimated $5.37M sold.

Based on aggregated 13F filings for Q1 2016.